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Introduction
Atherosclerosis begins in childhood. Several studies, such as the 
PDAY (Pathobiological Determinants of Atherosclerosis in Youth) 
study and the Bogalusa study, have demonstrated that fatty 
streaks occur in the aorta and coronary arteries within the first few 
decades and that much more advanced lesions are present in a 
significant portion of adolescents and young adults.1,2 These studies 
have also demonstrated that the major traditional risk factors for 
atherosclerosis and cardiovascular disease, namely hyperlipidaemia, 
hypertension, cigarette smoking, obesity and diabetes mellitus, are 
strongly associated with the presence and extent of arterial lesions. 
It is estimated that 75% to 90% of the current cardiovascular disease 
epidemic is related to these risk factors.3
Atherosclerosis is now the leading cause of death worldwide, not 
only in developed countries but also in developing countries. In 
South Africa, cardiovascular disease is second only to HIV as the 
major cause of death. We are therefore facing a ‘double burden’ 
of disease – HIV on the one hand and, with rapid urbanisation and 
lifestyle change, an emerging epidemic of cardiovascular disease 
on the other.
Not uncommonly, the first presentation of atherosclerosis is sudden 
cardiac death.4 It therefore makes sense that risk-factor modification 
to prevent the development or delay the onset of atherosclerosis 
needs to begin early in life.
Diet and lifestyle
Dietary intervention is the key component for the primary prevention 
of hyperlipidaemia. Reduced intake of saturated fat and cholesterol 
lowers total and LDL cholesterol. Controlling calorie intake and 
restricting carbohydrate and refined sugar intake are also important 
in the prevention of hypertriglyceridaemia and obesity. However, 
implementing dietary changes in young children and adolescents 
has been controversial, as there has been a concern that diets low 
in cholesterol and saturated fat might interfere with normal sexual 
maturation. There is no evidence for this, however, and two recent 
studies, the STRIP (Special Turku Coronary Risk Factor Intervention 
Project) study and the DISC (Dietary Intervention Study in Children) 
study, have shown that dietary intervention with restriction of fat and 
cholesterol is both safe and effective when applied from as young as 
seven months of age in children at risk for hypercholesterolaemia.5-7 
This is supported by the recent Consensus Statement from the 
American Heart Association on dietary recommendations for 
children and adolescents.3 These recommendations stress a diet 
high in fruit and vegetables, whole grains, beans, fish and lean meat, 
and emphasise reduced intake of saturated and trans-fatty acids, 
cholesterol and added sugar. The Guidelines also emphasise energy 
intake and physical activity appropriate for the maintenance of a 
normal, healthy weight for height (see Table I).
Adherence to a healthy diet can reduce LDL cholesterol levels by 
12% to 16%.8 Such a diet also reduces the risk of obesity, which is 
becoming epidemic worldwide, even in children.
Abstract
Atherosclerosis begins in childhood. Not uncommonly, the first presentation of atherosclerosis is sudden cardiac death. It therefore makes 
sense that risk-factor modification to prevent the development or delay the onset of atherosclerosis needs to begin early in life. Dietary 
intervention is the key component for the primary prevention of hyperlipidaemia. However, if diet and lifestyle fail to correct hyperlipidaemia, 
drug therapy may have to be considered. All children and adolescents with high-risk lipid disorders such as familial hypercholesterolaemia 
(FH), those with diabetes mellitus or other cardiovascular disease risk factors or with a family history of premature coronary artery disease 
should be considered for lipid-lowering therapy if diet and lifestyle intervention are ineffective. There are now numerous studies that have 
documented the safety and efficacy of statin therapy in both children and young adults. Based on these studies, it is now recommended that 
statin therapy be initiated in all male FH children from the age of ten years and at the onset of menses in females with FH. The initiation of 
statin therapy could be considered even earlier in FH children at high risk.
JEMDSA 2009;14(1):09-12
10
Review Article:  Hypercholesterolaemia in children and young adults 
2009 Volume 14 No 1JEMDSA
Adolescence is a nutritionally vulnerable developmental stage 
because of hormonal changes and because the growth rate 
accelerates. Currently, adolescents tend to have an increased 
intake of calorie-dense sweetened beverages, fries, pizzas and fast 
foods, particularly hamburgers, and a consequent lack of intake 
of recommended fruits, vegetables other than potatoes, lean meat 
and fish. In fact, fried potatoes make up a substantial portion of the 
vegetable intake! This, together with the more sedentary lifestyle 
due to a decline in participation in recreational sports, is fuelling 
the obesity epidemic and resulting in the development of type 
2 diabetes mellitus in teenagers. A specific problem is that many 
parents in South Africa, particularly amongst the African population, 
still believe that a fat baby or a chubby toddler is healthy. In order to 
prevent obesity and optimise nutrition, parents should try to adhere 
to current AHA recommendations (see Table II).
Lipid-lowering drug therapy
Drug therapy for hyperlipidaemia in children and adolescents has 
been controversial. However, recent clinical trials have shown 
that effective lowering of LDL cholesterol in children with familial 
hypercholesterolaemia or in those with severe hyperlipidaemia is 
both safe and effective and can delay or even prevent the onset of 
atherosclerosis. The AHA has recently issued a scientific statement 
highlighting this new evidence supporting drug therapy for the 
treatment of hyperlipidaemia in children and adolescents at high 
cardiovascular risk.9
All children and adolescents with high-risk lipid disorders such as 
familial hypercholesterolaemia, those with diabetes mellitus or other 
cardiovascular disease risk factors, or a family history of premature 
coronary artery disease should be considered for lipid-lowering 
therapy if lifestyle intervention is ineffective.9
a) Familial hypercholesterolaemia
Familial hypercholesterolaemia (FH) is a common genetic disorder 
affecting approximately 1:500 persons or 10 million people 
worldwide.10 In South Africa, probably because of a founder effect, 
the condition is even more highly prevalent in the Afrikaner, Jewish 
and Asian populations, with an estimated gene frequency of 1:80 to 
1:100.11 There are probably more than 100 000 affected persons 
in South Africa, the vast majority undiagnosed and untreated. The 
diagnosis of FH can by and large be made clinically. There is usually 
a family history of premature coronary artery disease, one parent 
will have hypercholesterolaemia and may well have the clinical signs 
of FH, namely arcus cornealis and thickening of the tendo-Achilles 
(see Figures 1 and 2).
Thickening of the tendo-Achilles is almost pathognomonic of FH 
and can also be found in adolescents and young adults with the 
condition, although less frequently.10
FH is characterised by exposure to severely elevated LDL cholesterol 
levels from birth onwards, which, if untreated, strongly predispose 
to premature atherosclerosis. In fact, children with FH have been 
shown to have impaired endothelial function and increased carotid 
intima-media thickness, both which are surrogate markers of 
atherosclerosis at a very young age. Impairment of endothelial 
function is already evident at the age of seven years,12 and carotid 
Table I: AHA paediatric dietary strategies for individuals aged >2 years:  











Table II: Guidelines for improving nutrition in young children3
•	 Parents	choose	meal	times,	not	children.
•	 Provide	a	wide	variety	of	nutrient-dense	foods,	such	as	fruits	and	vegetables,	
instead of high-energy density/nutrient-poor foods such as salty snacks, ice 





particular, restrict use of sweet/sweetened beverages as snacks (e.g. juice, soda, 
sports drinks).
•	 Limit	sedentary	behaviours,	with	no	more	than	one	or	two	hours	per	day	of	video	
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intima-media thickness is significantly increased by the age of 12 
years.13 Myocardial ischaemia and coronary artery stenosis have 
also been well documented in young adults with heterozygous FH. 
The risk of a fatal or non-fatal cardiovascular event by age 60 years 
in FH subjects is at least 50% in men and about 30% in women. 
In young adults with FH and aged 20 to 40 years, the relative risk 
of a fatal coronary event is increased 100-fold!10 This should be 
compared to other “traditional” risk factors, such as hypertension 
and smoking, which only increase the relative risk by about three- to 
fivefold.
Importantly, risk estimates for a standard cardiovascular event 
using risk charts such as the Framingham risk score seriously 
underestimate risk in subjects with FH. These charts should not be 
used if the total cholesterol is > 7.25 mmol/l.
b)  Other causes of high risk hyperlipidaemia in children and 
adolescents
A number of conditions other than genetic lipid disorders, such as 
FH associated with hyperlipidaemia, can also place a child at high 
risk for atherosclerosis. These conditions include diabetes mellitus, 
organ transplantation, HIV infection, connective tissue disease and 
chronic kidney disease.9
More than 50% of mortality in diabetic patients is related to 
coronary artery disease (CAD) and, for this reason, diabetes mellitus 
is now considered a CAD risk equivalent. Dyslipidaemia should 
therefore be looked for in all young diabetics, especially those with 
microalbuminuria or proteinuria. If dietary therapy and improved 
glycaemic control do not correct the dyslipidaemia, lipid-lowering 
drug therapy should be considered.
Up	 to	 50%	 of	 HIV-infected	 children	 treated	 with	 highly	 active	
antiretroviral (HAART) therapy develop lipid abnormalities, most 
commonly an increase in total and LDL cholesterol levels.14 This 
is seen particularly with the use of the protease inhibitors. In HIV-
infected adults, lipoprotein abnormalities have been shown to be 
associated with an increased risk for cardiovascular disease, and 
the same probably holds true for children.
Lipid abnormalities are also commonly observed in paediatric 
patients following all types of solid organ transplantation, in 
children with connective tissue diseases such as systemic lupus 
erythematosis (SLE), and in those with kidney diseases such as 
nephrotic syndrome.
Drug therapy with retinoids, which are commonly used for the 
treatment of acne, can also elevate total cholesterol and triglyceride 
levels, although this reverses when therapy is discontinued.
Important secondary causes of hyperlipidaemia are shown in 
Table III. These need to be considered in all children and adolescents 
with hyperlipidaemia.
Obesity and overweight should prompt the need for a lipogram in 
children and adolescents. These children should also be screened 
for other components of the metabolic syndrome (elevated blood 
pressure, elevated triglycerides, low HDL cholesterol and high 
fasting glucose levels). The metabolic syndrome predisposes to 
type 2 diabetes mellitus and has recently been shown to predict 
cardiovascular disease in adults, increasing the risk approximately 
15-fold.15 Diet and lifestyle interventions therefore need to be 
instituted early and aggressively in such children.
Which drug to use?
Until	 recently,	 only	 dietary	 intervention	 and/or	 bile	 acid-binding	
resins, e.g. cholestyramine, were recommended for the treatment 
of FH in children, but efficacy and compliance were both very 
poor. The HMG CoA reductase inhibitors or statins work by 
inhibiting the rate-limiting enzyme, HMG CoA reductase, for the 
endogenous synthesis of cholesterol. This leads to the depletion 
of the intracellular cholesterol pool, which triggers an upregulation 
of LDL surface receptors, leading to increased clearance of LDL 
from the circulation. Statin therapy has resulted in significant 
reductions in cardiovascular and all-cause mortality in adults at 
risk for, and with, manifest cardiovascular disease and are now also 
the preferred agent for treating hypercholesterolaemia in children 
and adolescents who meet the criteria for drug therapy.9,16 Adverse 
effects are uncommon or even rare, but include infrequent gastro-
intestinal upset, elevation of liver enzymes, myalgia and, very rarely, 
rhabdomyolysis. However, on the basis of current evidence, the risk 
of liver- or muscle-related adverse events is so small that this is 
not a reason to withhold statin therapy in high-risk children and 
adolescents, especially those with FH. Randomised control trials of 
up to four years in children have shown that statin therapy does 
not impair growth or sexual development.16,17 The safety of statin 
therapy during pregnancy is uncertain, however, and statin therapy 
should therefore be discontinued during pregnancy.
There are now numerous studies that have documented the safety 
and efficacy of statin therapy in both children and young adults. Based 
on these studies, the AHA now recommends initiating treatment with 
statin therapy in childhood at the age of ≥ 10 years in males and 
at the onset of menses in females. However, the initiation of statin 
therapy should be considered even earlier in FH children at ‘high 
risk’.9,18 (See Table IV.)
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How low to go?
Few studies have addressed the goal of LDL cholesterol in young 
children. However, more aggressive LDL cholesterol reduction has 
recently been shown to delay the progression of and even cause the 
regression of early atherosclerosis as assessed by carotid intima-
media thickness in children with FH.19
In my opinion, the LDL cholesterol goals of therapy should be the 
same in children as in adults, namely an LDL cholesterol of below 
3 mmol/l in most and a more aggressive goal of < 2.5 mmol/l in 
those with established cardiovascular disease (coronary artery 
disease, carotid plaque or peripheral vascular disease) or those with 
multiple other CAD risk factors (diabetes, smoking).
High-dose statin therapy may be required to achieve these goals. 
The efficacy of the different statins currently available in South Africa 
is shown in Table V.
Statin therapy alone may not always achieve these goals. Further 
reduction in LDL cholesterol could be achieved with the addition 
of a cholesterol-absorption inhibitor, such as ezetimibe, which will 
reduce the LDL cholesterol consistently by another 16% to 20%, 
with minimal adverse effects. A better-tolerated bile acid resin than 
cholestyramine, namely colesevelam, is currently undergoing clinical 
trials in children with FH and could be another option in the future in 
combination with statin therapy.
Carotid artery plaque has been shown to be present in about 10% 
of children with FH compared to no plaque in unaffected siblings. 
A recent study has also shown that introducing statin therapy early 
in young patients with FH can significantly delay the progression of 
atherosclerosis.17 This study supports the concept of initiating statin 
therapy for those with FH in childhood.
In my opinion, we should adopt ‘the younger the better’ option rather 
than ‘later but greater’ if we want to reduce the high cardiovascular 
morbidity and mortality associated with FH.20 We should not wait 
until the basin overflows, but should rather just ‘turn off the tap’.
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such as diabetes, HIV infection, connective tissue disease
Table V: Comparative efficacy of five currently available statins on lipids 
and lipoproteins
